165950-84-5

Basic information

• Product Name: (S)-5,6,7,8-Tetrahydro-6-(propylamino)-1-naphthalenol hydrobromide
• Synonyms: (6S)-(-)-5-Hydroxy-N-propyl-2-aminotetralin hydrobromide;(S)-5,6,7,8-Tetrahydro-6-(propylamino)-1-naphthalenol hydrobromide;(S)-2-NaphthalenaMine, 1,2,3,4-tetrahydro-5-hydroxy-N-propyl-, hydrobroMide;(S)-6-(Propylamino)-5,6,7,8-tetrahydronaphthalen-1-ol hydrobromide;(2S)-2-(Propylamino)tetralin-5-ol hydrobromide;(6S)-6-(Propylamino)-5,6,7,8-tetrahydronaphthalen-1-ol hydrobromide;6S)-(-)-5-Hydroxy-N-propyl-2-aminotetralin;(6S)-6-(propylamino)-5,6,7,8-tetrahydronaphthalen-1-ol
• CAS NO: 165950-84-5
• Molecular Formula: C13H19NO.HBr
• Molecular Weight: 286
• Mol File: 165950-84-5.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• Density: 1.4g/cm3 at 20℃
• Vapor Pressure: 0-0Pa at 20-25℃
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: (S)-5,6,7,8-Tetrahydro-6-(propylamino)-1-naphthalenol hydrobromide(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-5,6,7,8-Tetrahydro-6-(propylamino)-1-naphthalenol hydrobromide(165950-84-5)
• EPA Substance Registry System: (S)-5,6,7,8-Tetrahydro-6-(propylamino)-1-naphthalenol hydrobromide(165950-84-5)

Safety Data

• Hazardous Substances Data: 165950-84-5(Hazardous Substances Data)

Usage

General Description

(S)-5,6,7,8-Tetrahydro-6-(propylamino)-1-naphthalenol hydrobromide, also known as propylamino-tetralin (PAT), is a chemical compound that belongs to the class of naphthalenol derivatives. It is commonly used as a research tool in neuroscience, specifically in the study of serotonin receptors and their effects on behavior and physiology. PAT acts as a selective serotonin 5-HT1A receptor agonist, meaning it binds to and activates these receptors in the brain, leading to changes in serotonin signaling and neurotransmission. It has been studied for its potential therapeutic applications in the treatment of anxiety, depression, and other mood disorders. PAT is typically administered in a salt form, such as the hydrobromide salt, for improved solubility and bioavailability in research applications.

InChI:InChI=1/C13H19NO.BrH/c1-2-8-14-11-6-7-12-10(9-11)4-3-5-13(12)15;/h3-5,11,14-15H,2,6-9H2,1H3;1H/t11-;/m0./s1

Upstream product

• 32940-15-1 5-methoxy-2-tetralone 
• 1352917-62-4 N-(methoxycarbonyl)-N-propyl-5-methoxy-2-aminotetralin 
• 1352917-69-1 (S)-N-(methoxycarbonyl)-N-propyl-5-methoxy-2-aminotetralin 
• 101403-24-1 (S)-(5-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-propylamine hydrochloride 
• 93601-86-6 (S)-(-)-(5-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)propylamine hydrochloride 
• 101403-25-2 (R)-1,2,3,4-tetrahydro-5-methoxy-N-propyl-naphthalen-2-amine 
• 3904-24-3 (5-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)propylamine hydrochloride 
• 1352917-68-0 (S)-1,2,3,4-tetrahydro-5-methoxy-N-propyl-naphthalen-2-ammonium (S)-2-methoxy-2-phenylacetate 
• 1352917-67-9 (S)-1,2,3,4-tetrahydro-5-methoxy-N-propyl-naphthalen-2-ammonium (S)-2-hydroxy-3-phenylpropionate 
• 1352917-66-8 (S)-1,2,3,4-tetrahydro-5-methoxy-N-propyl-naphthalen-2-ammonium (R)-2-(2-chlorophenyl)-2-hydroxyacetate 
• 78598-91-1 2-(N-propylamino)-5-methoxytetraline 
• 3880-88-4 SKF 87967 hydrochloride 

Downstream Products

• 125572-93-2 rotigotine hydrochloride 
• 99755-59-6 rotigotine 

Relevant articles and documents

IMPROVED PROCESS FOR THE PREPARATION OF CRYSTALLINE FORM II OF ROTIGOTINE

The present invention relates to an improved, environment friendly and cost effective process for the preparation of crystalline Form II of Rotigotine. Rotigotine, i.e. (6S)-6-{propyl[2-(2-thienyl) ethyl]amino}-5,6,7,8-tetrahydro-l-naphthalenol represented by structural formula (I), is used for the treatment of Parkinson's disease and Willis-Ekbom disease.

Novel Process for the Preparation of Nitrogen Substituted Aminotetralins Derivatives

The present invention provides an alternative synthesis of N-substituted aminotetralines comprising resolution of N-substituted aminotetralins of formula (II), wherein R1, R2 and R3 are as defined for compound of formula (I).

PROCESS FOR THE PREPARATION OF ROTIGOTINE

A process for the preparation of Rotigotine (I) and of pharmaceutically acceptable salts thereof, which comprises the reductive amination of an amine of formula 6 with the 2-thienylacetic acid-sodium boron hydride complex and which makes use of hydrobromide 5 as an intermediate (II) The process is advantageous from the industrial point of view in that it allows to obtain Rotigotine with high enantiomeric purity starting from optically active 5,6,7,8-tetrahydro-6-(S)-N-propylamino-1-methoxy-naphthalene (2), avoiding the use of dangerous reactives, the need for difficult chromatographic separation or the formation of by-products. Furthermore, two novel crystalline forms are disclosed.